<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756482</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-218-0103</org_study_id>
    <nct_id>NCT01756482</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)</brief_title>
  <acronym>Challenge</acronym>
  <official_title>Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV-A Memphis 37b Strain)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with a
      strain of Respiratory Syncytial Virus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in viral load measurements.</measure>
    <time_frame>Post initial dose of GS-5806/placebo to Day 12</time_frame>
    <description>Area under the curve for viral load as measured by qRT-PCR assay from the first viral load measurement post initial dose of GS-5806 or placebo through day 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of baseline symptoms</measure>
    <time_frame>Innoculation through Day 12</time_frame>
    <description>Change of baseline symptoms post initial dose of GS-5806 or placebo through Day 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>GS-5806</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-5806, powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar powder for oral solution in juice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar powder for oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5806</intervention_name>
    <description>GS-5806, powder for oral solution</description>
    <arm_group_label>GS-5806</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sugar powder for oral solution in juice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female

          -  Between 18 to 45 years old

          -  Body Mass Index of 18 to 33 kg/m2

        Exclusion Criteria:

          -  Acute or chronic medical illness

          -  Positive for Human Immunodeficiency Virus, Hepatitis B or C

          -  Nose or nasopharynx abnormalities

          -  Abnormal lung function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adeyi Adeyemi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retroscreen Virology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retroscreen Virology</name>
      <address>
        <city>London</city>
        <zip>E12AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2012</study_first_posted>
  <disposition_first_submitted>January 2, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 2, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 3, 2014</disposition_first_posted>
  <last_update_submitted>August 3, 2015</last_update_submitted>
  <last_update_submitted_qc>August 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory</keyword>
  <keyword>Syncytial</keyword>
  <keyword>Virus</keyword>
  <keyword>Infections</keyword>
  <keyword>RSV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

